GlobeNewsWire
10 Nov 2026, 20:50 UTC · 20h ago
Impact · against what's priced in
Exicure receives a modest liquidity injection of approximately $4.8 million from the sale of its GPC-100 program assets. While providing a short-term cash boost, the amount is relatively small for a biotech company's long-term runway.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Exicure agreed to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million).
Newannounced today, Nov 10, 2026
So whatThe $4.8M cash infusion provides a short-term liquidity boost to the balance sheet for the next quarter.
More positive than 76% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The sale of GPC-100 assets for KRW 6.5 billion (approx. $4.8 million) provides an immediate cash infusion to the balance sheet.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 63% of ticker scores this week
The company is generating immediate cash through the sale of its GPC-100 program assets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
10h ago
—
No price for XCUR right now — the quote feed didn't answer.
XCUR chart →
